If you train fasted or are over 50, take 10–15g of EAAs (not BCAAs). If you eat ≥1.6 g/kg/day of quality protein, skip both entirely — you're already at the ceiling.
BCAAs fire the anabolic signal. EAAs fire it AND provide the fuel. In a fasted state, BCAAs alone can produce the opposite of what you're paying for.
BCAAs are the essential peri-workout supplement for maximising muscle growth. Leucine triggers anabolism, and since BCAAs represent roughly 35% of the amino acids in muscle protein, flooding the bloodstream with them during training should translate directly into bigger muscles. EAAs, by contrast, are viewed as an expensive, unnecessary upgrade — marketing aimed at people who already know too much.
The commercial fitness narrative is straightforward: BCAAs = leucine signal = muscle. Most gym-goers have two boxes of BCAAs in their supplement cupboard and zero awareness that this debate was largely settled in 2017 — and not in BCAAs' favour.
BCAAs cannot independently produce net muscle protein gain in a fasted state. HIGH
Wolfe (2017, JISSN) demonstrated through stable-isotope kinetic modelling that isolated BCAA administration actually decreases both muscle protein synthesis and breakdown, resulting in net negative protein balance. The mechanism is counterintuitive: leucine stimulates mTORC1 (the anabolic signalling pathway) so aggressively that the body demands all nine EAAs to complete construction of new muscle protein. When the other six EAAs aren't provided exogenously, the body breaks down its own muscle to harvest them. Signal without substrate equals a net catabolic outcome.
EAAs are hierarchically superior across every anabolic metric. HIGH
Moberg et al. (2016) established the post-exercise anabolic response hierarchy using both mTORC1 phosphorylation and the downstream p70S6K1 target:
A 15g EAA bolus overcomes anabolic resistance in older adults. HIGH
Paddon-Jones et al. (2004) demonstrated that a single 15g oral bolus of free-form EAAs stimulated Mixed Muscle Fractional Synthetic Rate equally in young (34±4 years) and older (67±2 years) adults — completely bypassing age-related anabolic resistance. Børsheim et al. (2008) extended this to 16 weeks: 22g EAA/day with no mandated exercise produced +1.14 kg lean mass and +22.2% lower-body strength in glucose-intolerant older adults. There is no comparable longitudinal BCAA dataset.
BCAAs have one legitimate use: CNS anti-fatigue during fasted endurance training. MODERATE
During prolonged fasted or low-carbohydrate endurance exercise, BCAAs compete with tryptophan for the LAT1 transporter across the blood-brain barrier. By limiting tryptophan entry, they reduce central serotonin production and delay CNS fatigue. This is a neurological anti-fatigue mechanism — not an anabolic one. Gym users who feel they "train harder" on BCAAs are experiencing this neurological effect. It's a real benefit, but it's entirely separate from hypertrophy.
If dietary protein is adequate, both supplements are redundant. HIGH
Adults consuming ≥1.6 g/kg/day of high-quality protein already saturate their intracellular EAA pools and operate at the physiological ceiling for MPS. Morton (2018) — a systematic review and meta-analysis — found no additional hypertrophic benefit from protein or amino acid supplementation above this threshold. The BCAAs vs EAAs debate is clinically relevant only for fasted training, older adults, and extreme caloric restriction.
Extreme BCAA ratios (8:1:1 leucine) create competitive inhibition on the LAT1 transporter — blocking absorption of phenylalanine, histidine, and threonine from both food and supplements. The optimal range is ~30–40% leucine (roughly 4:1:1). More leucine is not always better.
The sharpest contradiction in this literature: do BCAAs produce a meaningful anabolic response or a catabolic outcome?
BCAAs alone increased myofibrillar protein synthesis rate by 22% post-exercise compared to placebo. BCAA supplements produce a measurable anabolic response.
BCAAs alone result in net negative protein balance at the whole-body level. In a fasted state, BCAAs produce a catabolic net outcome, not muscle growth.
Both are correct in different measurement frames. Jackman measured Fractional Synthetic Rate (FSR) — the rate of protein synthesis initiation over 4 hours. Wolfe measured Net Protein Balance — synthesis minus breakdown. BCAAs increase the efficiency of intracellular amino acid recycling, which boosts FSR. But without exogenous EAAs, net accretion cannot occur. Jackman himself noted the 22% increase was roughly 50% lower than the whey protein response. The industry cites Jackman; biochemists cite Wolfe. Both are right. Only one is commercially inconvenient.
Lab studies use sub-optimal protein intakes (0.8–1.2 g/kg/day) to unmask supplement effects. Most real-world athletes eat 1.6–2.2 g/kg/day. At adequate protein intake, neither BCAAs nor EAAs provide additional muscle benefit. Direction: be MORE conservative about expected benefit unless you're genuinely under-eating protein.
In controlled metabolic wards, BCAA dosing is precise and isolated. In real life, taking BCAAs mid-meal or post-meal competes with LAT1 absorption of dietary EAAs from food — potentially suppressing the very MPS you're trying to drive. Direction: the interaction is more complex than isolated lab conditions suggest.
The best BCAA evidence (Jackman 2017) measures a 4-hour acute protein synthesis window. The best hypertrophy evidence (Morton 2018) runs 12+ weeks. Acute signalling from BCAAs does not reliably predict long-term muscle gain when compared to complete EAAs or whole proteins. Trust the long-term data over the tracer studies.
Leucine acts as a pharmaconutrient that directly activates mTORC1 (mammalian target of rapamycin complex 1) — the master anabolic switch inside muscle cells. mTORC1 then phosphorylates two downstream targets: p70S6K1 and eIF4E-BP1, which together initiate the translation machinery that builds new muscle proteins.
Leucine turns the ignition. But it can't fill the tank. When BCAAs are ingested without the remaining 6 EAAs in a fasted state, mTORC1 fires aggressively — increasing demand for all EAAs to build muscle protein. To meet this demand, the body breaks down existing muscle to release the missing amino acids. Net result: more muscle breakdown than synthesis. A net catabolic state triggered by the supplement that's supposed to prevent it.
Free-form EAAs (or complete intact proteins) solve this problem at the root. They provide both the leucine signal AND the stoichiometric substrate — all nine essential amino acids required to complete the muscle protein structure. The mTORC1 signal fires, the raw material is present, and net positive protein accretion can occur. The two inputs are not interchangeable: signal without substrate cannot build anything.
Ageing causes anabolic resistance — a blunted muscular response to dietary protein. The leucine threshold required to stimulate MPS is higher, the anabolic window is shorter, and recovery between protein feedings is slower. Free-form EAAs (15–22g doses, ~40% leucine) reliably bypass this resistance. BCAAs have no equivalent evidence in this population. For older adults, EAAs are not optional — they're the only supplement category with direct clinical support for sarcopenia prevention.
Vegetarians and vegans have lower baseline muscle and brain creatine AND lower dietary EAA density. They are near-universal EAA responders and carry the full substrate-limitation risk from BCAA-only supplementation.
Fasted-state trainees — early morning lifters, Ramadan-period athletes, intermittent fasters — face the highest risk from BCAAs. In a fasted state, BCAAs activate mTORC1 with no exogenous EAAs available, and the catabolism risk is real. EAAs or a complete fast-digesting protein (whey, egg white) are the correct interventions in this context.
Well-fed athletes (≥1.6 g/kg/day protein, mixed whole-food diet) represent the majority of supplement buyers. For this population, neither BCAAs nor EAAs provide additional hypertrophic benefit. The commercial success of BCAA products depends almost entirely on selling supplements to people who don't need them.
EAA dosing follows a threshold-then-plateau model with distinct zones:
Leucine threshold: ~2–3g leucine per serving to maximally stimulate mTORC1 in young adults. Older adults may need 3–4g leucine (higher anabolic resistance).
Optimal EAA dose: 10–15g per serving with ~30–40% leucine. This clears the leucine threshold while providing sufficient substrate for net positive protein accretion.
Saturation ceiling: Beyond ~15–20g free-form EAAs or ~30–40g whey, surplus amino acids are diverted to hepatic oxidation. No benefit from larger single doses — spread across meals instead.
For older adults specifically: 3–4 EAA doses per day (rather than one large dose) may better sustain elevated MPS rates, given the shorter anabolic window associated with ageing.
BCAAs became dominant through a classic mechanistic over-extension: leucine activates mTORC1, therefore more leucine equals more muscle. This was correct about the signal but catastrophically wrong about the substrate. The early BCAA literature (largely 1980s–2000s) measured acute signalling markers, not long-term hypertrophy, and didn't control for background protein intake. By the time Wolfe's 2017 net-balance data landed, BCAAs were already a multi-billion dollar category.
There's also a structural research bias: supplement companies fund research designed to detect FSR increases, not net protein balance. Positive short-term BCAA studies (like Jackman 2017) produced press releases. The peer-reviewed critique of Dudgeon's mathematical inconsistencies did not. The evidence favourable to BCAAs is amplified; the evidence unfavourable is suppressed by market incentives.
Finally, the subjective experience is genuine — the CNS anti-fatigue effect during fasted training produces real improvements in perceived performance. Users attribute this to muscle-building effects rather than the tryptophan competition mechanism. The product feels like it's working. When something feels like it works, you don't look for the mechanism.
EAAs are fundamentally superior to BCAAs for muscle protein synthesis. BCAAs alone are virtually useless for hypertrophy when dietary protein is adequate, and actively counterproductive in fasted states (net catabolic outcome). EAAs are the evidence-based choice for older adults and fasted training states.
What would change this: A rigorous 12-week double-blind RCT with dietary protein clamped at 1.0 g/kg/day, comparing isonitrogenous BCAAs vs EAAs on myofibrillar cross-sectional area via MRI and D3-creatine dilution. If BCAAs matched EAAs for long-term muscle growth under these conditions, the substrate bottleneck hypothesis would be overturned. No such trial exists.
The core findings (EAAs > BCAAs, substrate bottleneck mechanism, older-adult dosing data) are well-replicated and mechanistically sound. The main uncertainty is population specificity — most high-quality studies use controlled lab conditions that don't map cleanly to real-world athletes on mixed diets. Individual variation in leucine sensitivity and gut amino acid absorption also affects response. This isn't medical advice; anyone with kidney disease, metabolic disorders, or eating disorder history should consult a registered dietitian before adjusting amino acid supplementation protocols.
How strong is the evidence for the claims in this review? Higher = more confidence the claims are supported. This does not measure how large the effect is or how important it is compared with other levers.
Is this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.
Evidence-scored dosing, timing, forms, and who should skip it. One page, no fluff.
Get the protocolConviction-scored verdicts on supplements, nutrition, training, physio, and recovery.